vs
Side-by-side financial comparison of Eastern Bankshares, Inc. (EBC) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $295.9M, roughly 1.1× Eastern Bankshares, Inc.). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs 13.2%, a 8.9% gap on every dollar of revenue. On growth, Eastern Bankshares, Inc. posted the faster year-over-year revenue change (710.6% vs -2.7%). Over the past eight quarters, Eastern Bankshares, Inc.'s revenue compounded faster (38.6% CAGR vs 0.4%).
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
EBC vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $339.0M |
| Net Profit | $65.3M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | — | 19.9% |
| Net Margin | 22.1% | 13.2% |
| Revenue YoY | 710.6% | -2.7% |
| Net Profit YoY | -34.4% | 19.3% |
| EPS (diluted) | $0.29 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $295.9M | — | ||
| Q4 25 | $37.5M | $339.0M | ||
| Q3 25 | $241.5M | $327.3M | ||
| Q2 25 | $244.9M | $321.4M | ||
| Q1 25 | $31.1M | $330.6M | ||
| Q4 24 | $216.5M | $348.5M | ||
| Q3 24 | $203.4M | $345.5M | ||
| Q2 24 | $154.0M | $336.2M |
| Q1 26 | $65.3M | — | ||
| Q4 25 | $99.5M | $44.7M | ||
| Q3 25 | $106.1M | $38.7M | ||
| Q2 25 | $100.2M | $34.0M | ||
| Q1 25 | $-217.7M | $58.0M | ||
| Q4 24 | $60.8M | $37.5M | ||
| Q3 24 | $-6.2M | $33.8M | ||
| Q2 24 | $26.3M | $38.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.9% | ||
| Q3 25 | 38.9% | 17.9% | ||
| Q2 25 | 41.0% | 16.8% | ||
| Q1 25 | -590.9% | 21.6% | ||
| Q4 24 | 33.3% | 16.9% | ||
| Q3 24 | -1.6% | 15.0% | ||
| Q2 24 | 24.7% | 11.8% |
| Q1 26 | 22.1% | — | ||
| Q4 25 | 265.6% | 13.2% | ||
| Q3 25 | 44.0% | 11.8% | ||
| Q2 25 | 40.9% | 10.6% | ||
| Q1 25 | -699.2% | 17.5% | ||
| Q4 24 | 28.1% | 10.8% | ||
| Q3 24 | -3.0% | 9.8% | ||
| Q2 24 | 17.1% | 11.4% |
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.48 | $0.95 | ||
| Q3 25 | $0.53 | $0.81 | ||
| Q2 25 | $0.50 | $0.70 | ||
| Q1 25 | $-1.08 | $1.17 | ||
| Q4 24 | $0.29 | $0.74 | ||
| Q3 24 | $-0.03 | $0.66 | ||
| Q2 24 | $0.16 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $551.7M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $4.3B | $911.5M |
| Total Assets | $30.6B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $551.7M | — | ||
| Q4 25 | $507.6M | $363.4M | ||
| Q3 25 | $703.4M | $296.4M | ||
| Q2 25 | $948.3M | $292.9M | ||
| Q1 25 | $609.0M | $306.8M | ||
| Q4 24 | $1.9B | $320.8M | ||
| Q3 24 | $1.7B | $299.3M | ||
| Q2 24 | $1.4B | $344.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $911.5M | ||
| Q3 25 | $3.8B | $849.2M | ||
| Q2 25 | $3.7B | $882.3M | ||
| Q1 25 | $3.6B | $820.8M | ||
| Q4 24 | $3.6B | $906.9M | ||
| Q3 24 | $3.7B | $878.9M | ||
| Q2 24 | $3.0B | $905.4M |
| Q1 26 | $30.6B | — | ||
| Q4 25 | $30.6B | $2.5B | ||
| Q3 25 | $25.5B | $2.4B | ||
| Q2 25 | $25.5B | $2.5B | ||
| Q1 25 | $25.0B | $2.5B | ||
| Q4 24 | $25.6B | $2.5B | ||
| Q3 24 | $25.5B | $2.5B | ||
| Q2 24 | $21.0B | $2.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $432.4M | $93.6M | ||
| Q3 25 | $157.1M | $111.3M | ||
| Q2 25 | $123.9M | $17.4M | ||
| Q1 25 | $47.3M | $116.6M | ||
| Q4 24 | $283.8M | $43.8M | ||
| Q3 24 | $108.3M | $48.8M | ||
| Q2 24 | $54.3M | $-27.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | 4.35× | 2.09× | ||
| Q3 25 | 1.48× | 2.88× | ||
| Q2 25 | 1.24× | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | 4.67× | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | 2.06× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBC
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
